Schedule 13G ownership disclosure

Allogene Therapeutics Inc

Common Stock · CUSIP: 019770106

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Arie Belldegrun, M.D.

    Shares: 13,248,170.00 · Class: 5.8%

  • Bellco Legacy LLC

    Shares: 539,867.00 · Class: 0.2%

  • Bellco Legacy IV LLC

    Shares: 4,710,120.00 · Class: 2.1%

  • Vida Ventures LLC

    Shares: 1,798,163.00 · Class: 0.8%

  • Vida Ventures III, L.P.

    Shares: 1,720,172.00 · Class: 0.8%

  • Vida Ventures III-A, L.P.

    Shares: 3,965.00 · Class: 0.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001296549-26-000004
Form type
SCHEDULE 13G/A
Filer
Allogene Therapeutics, Inc.
CIK
CIK 1737287
Filed
Feb 17, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub